Vardenafil Ameliorates Calcium Mobilization in Pulmonary Artery Smooth Muscle Cells from Hypoxic Pulmonary Hypertensive Mice

Archives of Medical Research

Volumn 43, Issue 4, 2012, Pages 265-273

  Chen, Wen Sheng ^a   Li, Xiao Qiang ^b   Cao, Wei ^b   Xiao, Xiong ^b   Dong, Ling ^b   Zhang, Jin Zhou ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Calcium signaling; Hypoxia; Pulmonary artery; Vardenafil

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA 1 ADRENERGIC RECEPTOR; CALCIUM ION; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; NEUROTRANSMITTER; PHENYLEPHRINE; POTASSIUM ION; VARDENAFIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CARDIOPULMONARY HEMODYNAMICS; CHRONIC DISEASE; CONTROLLED STUDY; DRUG MECHANISM; FLUORESCENCE; HEART RIGHT VENTRICLE HYPERTROPHY; HYPOXIA; INTRACELLULAR SIGNALING; MEMBRANE DEPOLARIZATION; MOUSE; MUSCLE CONTRACTION; MUSCLE TONE; NONHUMAN; PATCH CLAMP; PULMONARY ARTERY; PULMONARY HYPERTENSION; SARCOPLASMIC RETICULUM; SMOOTH MUSCLE FIBER; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; VASOCONSTRICTION;

ADENOSINE TRIPHOSPHATE; ADRENERGIC ALPHA-AGONISTS; ANIMALS; ANOXIA; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM SIGNALING; CHRONIC DISEASE; DRUG EVALUATION, PRECLINICAL; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; IMIDAZOLES; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; ION TRANSPORT; MALE; MICE; MICE, INBRED C57BL; MYOCYTES, SMOOTH MUSCLE; PATCH-CLAMP TECHNIQUES; PHENYLEPHRINE; PIPERAZINES; POTASSIUM; SARCOPLASMIC RETICULUM; SULFONES; TRIAZINES; VASODILATION; VASODILATOR AGENTS;

EID: 84864091494     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2012.05.004     Document Type: Article

References (32)

1. Raiesdana A., Loscalzo J. Pulmonary arterial hypertension. Ann Med 2006, 38:95-110.
2. Peinado V.I., Pizarro S., Barbera J.A. Pulmonary vascular involvement in COPD. Chest 2008, 134:808-814.
3. Pak O., Aldashev A., Welsh D., et al. The effects of hypoxia on the cells of the pulmonary vasculature. Eur Respir J 2007, 30:364-372.
4. 2+ channels and chronic hypoxia. Microcirculation 2006, 13:657-670.
5. Karaki H., Ozaki H., Hori M., et al. Calcium movements, distribution, and functions in smooth muscle. Pharmacol Rev 1997, 49:157-230.
6. Montani D., Chaumais M.C., Savale L., et al. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Adv Ther 2009, 26:813-825.
7. Archer S.L., Michelakis E.D. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med 2009, 361:1864-1871.
8. Rexhaj E., Bloch J., Jayet P.Y., et al. Fetal programming of pulmonary vascular dysfunction in mice: role of epigenetic mechanisms. Am J Physiol Heart Circ Physiol 2011, 301:H247-H252.
9. Hara Y., Sassi Y., Guibert C., et al. Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. J Clin Invest 2011, 121:2888-2897.
10. Li J., Zhang P., Zhang Q.Y., et al. Effects of U50,488H on hypoxia pulmonary hypertension and its underlying mechanism. Vascul Pharmacol 2009, 51:72-77.
11. 2+ in rabbit pulmonary artery smooth muscle cells through phospholipase C. Am J Physiol Heart Circ Physiol 2005, 289:H1551-H1559.
12. Batal O., Khatib O.F., Bair N., et al. Sleep quality, depression, and quality of life in patients with pulmonary hypertension. Lung 2011, 189:141-149.
13. Rabe K.F., Tenor H., Dent G., et al. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol 1994, 266:L536-L543.
14. Ryerson C.J., Nayar S., Swiston J.R., et al. Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Respir Res 2010, 11:12.
15. Vlachopoulos C., Ioakeimidis N., Rokkas K., et al. Cardiovascular effects of phosphodiesterase type 5 inhibitors. J Sex Med 2009, 6:658-674.
16. Rosen R.C., Kostis J.B. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol 2003, 92:9M-18M.
17. Tsai B.M., Turrentine M.W., Sheridan B.C., et al. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression. Ann Thorac Surg 2006, 81:272-278.
18. Ghofrani H.A., Voswinckel R., Reichenberger F., et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004, 44:1488-1496.
19. Rosenblum W.D. Pulmonary arterial hypertension: pathobiology, diagnosis, treatment, and emerging therapies. Cardiol Rev 2010, 18:58-63.
20. Teixeira C.E., Priviero F.B., Webb R.C. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta. J Pharmacol Exp Ther 2006, 316:654-661.
21. Lau L.C., Adaikan P.G. Mechanisms of direct relaxant effect of sildenafil, tadalafil and vardenafil on corpus cavernosum. Eur J Pharmacol 2006, 541:184-190.
22. 2+ entry by store depletion or hypoxia in canine pulmonary arterial smooth muscle cells. Br J Pharmacol 2007, 152:101-111.
23. Janiak R., Wilson S.M., Montague S., et al. Heterogeneity of calcium stores and elementary release events in canine pulmonary arterial smooth muscle cells. Am J Physiol Cell Physiol 2001, 280:C22-C33.
24. Maas O., Donat U., Frenzel M., et al. Vardenafil protects isolated rat hearts at reperfusion dependent on GC and PKG. Br J Pharmacol 2008, 154:25-31.
25. Burnstock G. Purinergic signalling. Br J Pharmacol 2006, 147(suppl 1):S172-181.
26. Hartley S.A., Kozlowski R.Z. Electrophysiological consequences of purinergic receptor stimulation in isolated rat pulmonary arterial myocytes. Circ Res 1997, 80:170-178.
27. 2+ concentration in rat pulmonary artery myocytes. Am J Physiol 1996, 271:L450-L458.
28. Toque H.A., Teixeira C.E., Priviero F.B., et al. Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets. Br J Pharmacol 2008, 154:787-796.
29. Ballard S.A., Gingell C.J., Tang K., et al. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998, 159:2164-2171.
30. Daugan A., Grondin P., Ruault C., et al. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6] pyrido[3,4-b]indole-1,4-dione analogues. J Med Chem 2003, 46:4533-4542.
31. Saenz de Tejada I., Angulo J., Cuevas P., et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001, 13:282-290.
32. Doggrell S.A. Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction. Expert Opin Pharmacother 2005, 6:75-84.